LONDON (ShareCast) - (Sharecast News) - Immunodiagnostics group Oncimmune said on Tuesday that it had signed two separate agreements for the use of its newly developed and proprietary Infectious Disease panel with Roche Pharmaceuticals and Cedars-Sinai Medical Center.
For Roche, Oncimmune will utilise its Infectious Disease panel to profile antibody and autoantibody responses in all patient samples from the group's COVACTA trial, with the pair's contract also including an option to extend to IgA and IgM antibody profiling, substantially increasing the value of the contract.

As far as Cedars-Sinai in Los Angeles was concerned, the AIM-listed group that it had entered into an agreement with to provide antibody profiling in Covid-19 samples as biomarkers. Following on from the first project, Cedars-Sinai also agreed to expand its collaborative coronavirus programme to study a unique cohort of patients.

Chief executive Dr Adam Hill said: "We are delighted to be strengthening our partnership with Roche and Cedars-Sinai through these two very important projects. As the world shifts its focus to recovering from the pandemic, we are seeing continued interest in Oncimmune's infectious disease offering.

"Today's announcement is further validation of the importance of our Infectious Disease panel in supporting both clinical research and the development of vaccines and therapeutics. We are also experiencing substantial interest in our immuno-oncology and autoimmune activities, which together with our infectious disease offering, provides us with confidence in the continued growth of ImmunoINSIGHTS."

As of 0910 BST, Oncimmune shares were up 2.63% at 195.0p.

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE